Summary of MicroPort Medical's Conference Call Company Overview - **Company**: MicroPort Medical - **Period**: First half of 2025 - **Revenue**: Approximately $550 million, a year-on-year decrease of 2% after excluding currency effects, but a quarter-on-quarter increase of 16% in domestic market revenue [2][3][23] Key Financial Metrics - **Gross Margin**: 56.4%, higher than expected [2][23] - **Net Loss**: Reduced by 66% to $36 million [2][25] - **EBITDA**: Increased by 116% to $128 million [2][25] - **Operating Expenses**: Decreased by 14.5% year-on-year [2][23] - **R&D Expenses**: Significantly reduced by 37% [2][23] - **Cash Reserves**: Increased to $1.04 billion [2][27] Business Performance Highlights - **International Business Growth**: Revenue from overseas operations grew by 57.3%, with significant contributions from: - Cardiac intervention overseas revenue up 95% - Neuroscience overseas revenue up 67.4% - MicroPort Robotics overseas market growth nearly tripled [2][3][12] - **Cardiovascular Intervention**: Net profit increased by 64.4%, with a net profit margin of 21% [2][11] - **Orthopedic Business**: Net loss significantly narrowed by 58%, with EBITDA growth of 29% [2][11] - **Heart Valve Business**: Net loss reduced by 96.2%, with TAVI implant volume reaching 2,146 cases [2][21] Strategic Developments - **New Strategic Investor**: Introduction of state-owned Shanshi Capital as a strategic shareholder, expected to enhance business expansion and governance [2][8][39] - **Business Restructuring**: Strategic reorganization of heart rhythm and management businesses to create a unique global cardiac product platform [2][8] Challenges Faced - **Market Pressures**: Challenges include price pressure from domestic centralized procurement, cautious hospital selections due to anti-corruption measures, and delays in new product approvals [4][16] - **Geopolitical Impact**: The orthopedic business faced revenue shortfalls due to US-China tariffs and geopolitical conflicts affecting the supply chain [6][31] Future Outlook - **Revenue Guidance**: Adjusted to high single-digit growth for the year, with cardiovascular business expected to grow by 15% and heart rhythm management adjusted to 6% [5][28][29] - **Innovation and Market Expansion**: Continued focus on innovation, expanding market reach, and enhancing supply chain flexibility [12][45] - **Debt Management**: Plans to reduce debt levels from approximately 70% to around 50% over the next 1-3 years [53][50] R&D and Product Development - **Clinical Trials**: Successful clinical trials for the Firehawk stent, reducing dual antiplatelet therapy duration from 12 months to 1 month for specific patients [10][38] - **New Product Approvals**: The domestic knee joint prosthesis received FDA approval, enhancing competitiveness in overseas markets [13][49] Conclusion - **Overall Performance**: MicroPort Medical demonstrated significant improvements in profitability and operational efficiency despite facing market challenges. The company is well-positioned for future growth through strategic partnerships, innovative product offerings, and a focus on international expansion [2][60]

Core Insights - The company reported a revenue of $548 million for 1H25, a year-on-year decrease of 2%, but the net loss attributable to shareholders narrowed to $47 million from $97 million, representing a 52% reduction in loss [1] - Despite revenue pressures, effective cost control and contributions from foreign exchange gains and asset disposals led to better-than-expected profit performance [1] Revenue Trends - Major business segments experienced varying degrees of revenue pressure: - Coronary revenue decreased by 2.1%, with domestic revenue stable and balloon and accessory revenues increasing by 38% and 21% respectively; overseas revenue fell by 10% due to Middle East conflicts and channel adjustments [1] - Orthopedic revenue declined by 3.7%, and cardiac rhythm management revenue decreased by 1.4% [1] - Revenue from large artery and peripheral segments dropped by 9.2%, while neurointervention revenue fell by 6.2% [1] - Structural heart disease revenue increased by 2.7%, surgical robot revenue surged by 77%, and surgical revenue rose by 42.8% [1] - International business revenue grew by 57.3%, reaching $60 million [1] Cost Management and EBITDA - The orthopedic segment's net loss narrowed by 57.9%, with EBITDA increasing by 28.5% [2] - Cardiac rhythm management achieved positive EBITDA, while Heartlink Medical's net loss decreased by 96.2% and minimally invasive robotics' net loss reduced by 58.9% [2] - Overall, total expenses decreased by 14.5% year-on-year, and the operating expense ratio improved by 8.1 percentage points, with R&D expense ratio dropping from 20.6% to 13.2% [2] - The company's overall EBITDA increased to $128 million from $59 million in 1H24 [2] Strategic Initiatives - The company plans to restructure its cardiac rhythm management business, with a potential merger with minimally invasive Heartlink's operations [2] - The company is also looking to sell several properties and other assets, engaging with multiple potential investors to improve its debt and cash flow situation [2] Profit Forecast and Valuation - The profit forecast for 2025/26 remains unchanged at a net profit of -$39 million and $74 million respectively, maintaining an outperform rating [2] - The target price based on DCF model remains at HKD 17, indicating a 40% upside potential from the current price [2]

Core Viewpoint - CICC maintains the profit forecast for MicroPort Medical (00853) for 2025/26 at -0.39/+0.74 billion USD, with an unchanged outperform rating and a target price of 17 HKD, indicating a 40% upside potential from the current price [1] Revenue Performance - The company's revenue for 1H25 was 5.48 billion USD, a year-on-year decrease of 2%, while the net loss attributable to shareholders was 0.47 billion USD, an improvement of 52% compared to the previous year's loss of 0.97 billion USD [1] - Major business segments faced revenue pressure: - Coronary revenue decreased by 2.1%, with domestic revenue stable and balloon and accessory revenues increasing by 38% and 21% respectively; overseas revenue fell by 10% due to Middle East conflicts and channel adjustments - Orthopedic revenue declined by 3.7%, and arrhythmia management revenue decreased by 1.4% - Revenue from large artery and peripheral segments dropped by 9.2%, while neurointervention revenue fell by 6.2% - Structural heart disease revenue increased by 2.7%, surgical robot revenue surged by 77%, and surgical revenue rose by 42.8% - The company's overseas business revenue grew by 57.3%, reaching 0.60 billion USD [2] Loss Reduction - The orthopedic segment's net loss narrowed by 57.9%, with EBITDA increasing by 28.5% year-on-year - The arrhythmia management business achieved positive EBITDA - MicroPort's overall EBITDA rose to 1.28 billion USD, up from 0.59 billion USD in 1H24 [3] Business Restructuring Plans - The company announced plans for a strategic restructuring of its arrhythmia management business, potentially merging it with MicroPort's heart management business - As of 1H25, the company had a share repurchase obligation of 2.54 billion USD related to the arrhythmia management business - The company is also planning to sell several properties and other assets, engaging with multiple potential investors for direct investments in subsidiaries or other assets, which may improve the group's debt and cash flow situation [4]

Core Viewpoint - CICC maintains the profit forecast for MicroPort Medical (00853) for 2025/26 at -0.39/+0.74 billion USD, with an outperform rating and a target price of 17 HKD, indicating a 40% upside potential from the current price [1] Group 1: Revenue Performance - The company's revenue for 1H25 was 5.48 billion USD, a year-on-year decrease of 2% [1] - Major business segments faced revenue pressure, with coronary revenue down 2.1%, orthopedic revenue down 3.7%, and arrhythmia management revenue down 1.4% [2] - Structural heart disease revenue increased by 2.7%, surgical robot revenue surged by 77%, and surgical revenue rose by 42.8% [2] - The overseas business revenue grew by 57.3%, reaching 0.60 billion USD [2] Group 2: Loss Reduction and Cost Management - The orthopedic segment's net loss narrowed by 57.9%, with EBITDA increasing by 28.5% [3] - The company achieved a positive EBITDA in the arrhythmia management business [3] - Overall, the company's total expenses decreased by 14.5%, and the operating expense ratio improved by 8.1 percentage points [3] - R&D expense ratio decreased from 20.6% to 13.2% [3] - Overall EBITDA increased to 1.28 billion USD, compared to 0.59 billion USD in 1H24 [3] Group 3: Business Restructuring Plans - The company is considering a non-binding proposal for a strategic restructuring of the arrhythmia management business, potentially merging it with MicroPort Heart [4] - The company plans to sell several properties and other assets, engaging with multiple potential investors for direct investments [4] - These activities are expected to improve the company's debt and cash flow situation [4]

Market Performance - A-shares continued strong performance with the Shanghai Composite Index reaching a high of 3879.05 points, closing at 3862.65 points, up 0.12% [2] - The Shenzhen Component Index and the ChiNext Index rose by 0.11% and 0.55% respectively [2] Gold Market - The precious metals sector saw significant gains, with international gold prices reaching new highs; COMEX gold peaked at $3552 per ounce, marking a year-to-date increase of approximately 35% [6][8] - London spot gold prices also rose, reaching $3486.16 per ounce, just shy of the historical high of $3500 from April [8] - A-share gold stocks surged, with Western Gold hitting the daily limit, and several other stocks like Xiaocheng Technology and Hunan Gold also showing strong gains [8][9] AI Computing Sector - The AI computing sector exhibited mixed performance; stocks like Xuanji Information and Liyang Chip hit the daily limit, while Cambrian experienced a decline of nearly 3% [10][11] - Cambrian's stock fluctuated significantly, dropping over 8% before stabilizing to a decrease of 2.98% by midday [11][12] - Reports indicated that rumors about Alibaba purchasing 150,000 Cambrian GPUs were unfounded [12] Alibaba's Market Activity - Alibaba's stock surged over 16% in Hong Kong, with a market capitalization increase of approximately HKD 400 billion, reaching a total market value of HKD 2.59 trillion [15][16] - The company reported a revenue of RMB 247.65 billion for Q1 of the 2026 fiscal year, with a net profit of RMB 43.12 billion, reflecting a 76% year-on-year increase [15][17] - Alibaba plans to invest RMB 380 billion over three years in AI infrastructure, which is expected to drive demand for computing power [17] Innovative Drug Sector - The innovative drug sector saw significant activity, with MicroPort Medical rising over 14% and achieving a year-to-date increase of over 109% [18] - MicroPort's new stent technology demonstrated clinical advantages, reducing treatment duration and complications [18] - The approval of 43 innovative drugs in the first half of the year indicates a growing focus on drug development in China, with the biotech index showing a year-to-date increase of over 101% [18]

Group 1: Hong Kong Stocks Performance - BYD Electronics (00285) rose over 7%, reporting a nearly 14% year-on-year increase in net profit for the first half of 2025, with positive progress in AI data center business [1] - Beihai Kangcheng-B (01228) surged over 11%, achieving profitability in the first half of the year and recently forming a strategic partnership with Baiyang Pharmaceutical [1] - MicroPort Medical (00853) increased over 11%, with a reported loss of $46.602 million for the first half of 2025, a 51.9% reduction in loss year-on-year [1] - Bank of China Hong Kong (02388) rose over 6%, reporting a net profit of HKD 22.12 billion for the first half of 2025, with an increase in net trading income year-on-year [1] - UBTECH (09880) increased over 4%, announcing a strategic partnership agreement worth $1 billion with international investment firm Infini Capital [1] - Gold stocks performed well, with China Silver Group (00815) up over 8%, Zhaojin Mining (01818) up over 7%, Shandong Gold (01787) up over 6%, Chifeng Jilong Gold (06693) up over 6%, and Zijin Mining (02899) up over 6%, driven by rising gold prices due to increased interest rate cut expectations [1] Group 2: Chinese Companies' Financial Results - China Communications Construction (01800) fell over 5%, reporting a 16.9% year-on-year decrease in net profit for the first half of 2025 and not declaring an interim dividend [2] - Evergrande Property (06666) declined over 3%, with a 5.6% year-on-year drop in net profit for the first half of the year, with management expressing pessimism about economic benefits from Evergrande Group [2] - Zoomlion Heavy Industry (01157) rose over 2%, reporting a more than 20% year-on-year increase in net profit for the first half of 2025, with institutions optimistic about export growth in the second half [2] - Midea Group (00300) increased over 2%, reporting a 25.04% year-on-year increase in net profit for the first half of 2025 and proposing an interim dividend of HKD 5 per 10 shares [2] Group 3: US Stocks Performance - Autodesk (ADSK.US) rose 9.09%, reporting a 17% year-on-year revenue increase for the second fiscal quarter and raising its full-year revenue and adjusted EPS guidance [3] - Gap (GAP.US) increased 1.52%, with revenue slightly below market expectations for the second fiscal quarter, and management indicated that tariffs may pressure annual gross margins [3] - Marvell Technology (MRVL.US) fell 18.60%, reporting record revenue of $2.01 billion for the second quarter, a 58% year-on-year increase, but provided a Q3 revenue guidance slightly below expectations [3] - Alibaba (BABA.US) surged 12.90%, with a market value increase of $36.7 billion overnight, reporting an 18% year-on-year decline in Non-GAAP net profit, but strong resilience in core business [3] - Ambarella (AMBA.US) rose 16.78%, providing strong guidance for Q3 revenue, expected to be between $100 million and $108 million, reflecting continued growth in edge AI demand [3] - IREN Ltd (IREN.US) increased 14.93%, exceeding expectations in its fourth-quarter earnings report and announcing a priority partnership with NVIDIA [3] Group 4: Other Notable Stocks - Dell Technologies (DELL.US) fell 8.88%, reporting that its infrastructure division's operating profit margin was below expectations [4] - Affirm Holdings (AFRM.US) rose 10.59%, reporting better-than-expected revenue and profit for the fourth fiscal quarter [4] - TryHard Holdings (THH.US) declined 9.80%, issuing 1.5 million shares at $4 each, at the lower end of the pricing range [5] - GrowHub (TGHL.US) increased 1.48%, issuing 3.8 million shares at $4 each, also at the lower end of the pre-set pricing range [5]

Group 1 - The China Securities Hong Kong Stock Connect Medical Theme Index (932069) has risen by 2.99%, with notable increases in constituent stocks such as Chunli Medical (01858) up 10.49%, MicroPort Medical (00853) up 7.02%, and Crystal Technology Holdings (02228) up 6.89% [1] - The Hong Kong Medical ETF (159366) has also seen an increase of 2.44% [1] - The China Securities All Index Medical Device Index (H30217) has increased by 1.46%, with significant gains from Ji Min Health (603222) up 9.98%, Hualan Biological Engineering (301093) up 7.81%, and Huatai Medical (688617) up 6.93% [2][3] Group 2 - The FDA has accepted Vibration-Controlled Transient Elastography (VCTE) as an alternative endpoint for assessing liver fibrosis in patients with Metabolic Associated Steatotic Liver Disease (MASH), marking a significant breakthrough in non-invasive diagnostic technology [4] - This advancement is expected to enhance drug development efficiency for MASH and provide growth opportunities for domestic companies in the non-invasive companion diagnostics field [4] - The pharmaceutical and biotechnology sector showed marginal improvement in Q2 2025, with the innovative drug and CXO sectors performing particularly well, as the CXO industry rebounded with a 14% year-on-year revenue increase and a 54% increase in net profit [4] Group 3 - The domestic medical device industry is gradually recovering from an adjustment period, with market demand showing signs of recovery [5] - In Q2 2025, the medical equipment sector experienced a 5.26% year-on-year revenue growth, and the medical consumables sector maintained stable growth [5] - The Hong Kong Medical ETF (159366) focuses on rare medical segment leaders and has a high CXO content, while the Medical Device ETF (159883) is the largest in A-shares, covering various sub-sectors of the medical device industry [5]

Core Viewpoint - MicroPort Medical reported a revenue of approximately $547.5 million for the first half of 2025, reflecting a year-on-year decrease of 2% while the company narrowed its net loss to $46.6 million, a reduction of 51.9% compared to the previous year [1] Financial Performance - Revenue for the first half of 2025 was approximately $547.5 million, down 2% year-on-year [1] - The net loss attributable to equity shareholders was $46.6 million, which represents a 51.9% reduction in losses compared to the same period last year [1] - Basic loss per share was 2.53 cents [1] Cost Management - The total expenses for sales, management, and research and development decreased by 14.5% compared to the same period in 2024 [1] - The operating expense ratio improved by 8.1 percentage points year-on-year [1] - The research and development expense ratio decreased from 20.6% to 13.2% [1] Non-Core Business Disposal - The company completed the disposal of several non-core businesses during the reporting period, resulting in a positive gain of $26.1 million [1]

Core Insights - MicroPort Medical's Firehawk® drug-eluting stent system has shown promising results in the TARGET-FIRST clinical study, allowing for a reduction in dual antiplatelet therapy duration from 12 months to 1 month for low-risk acute myocardial infarction patients without increasing ischemic risk and significantly reducing bleeding complications [1] Group 1: Clinical Research and Findings - The TARGET-FIRST study results were published in the New England Journal of Medicine and presented at the European Society of Cardiology 2025 Congress, highlighting the significance of the findings in potentially changing global clinical practices [2] - Firehawk® stent previously gained attention for addressing late thrombosis issues in a separate European trial, indicating its clinical benefits and economic potential [3] Group 2: Product Features and Design - Firehawk® is a third-generation drug-eluting stent that combines low restenosis rates with low late thrombosis rates, utilizing a unique drug release mechanism that allows for targeted and timed drug delivery [4] - The stent's design features a drug load that is one-third of conventional stents and a coating area that constitutes about 5% of the total metal area, promoting rapid endothelial healing while maintaining the stent's drug-eluting properties [4] Group 3: Market Expansion and Future Plans - Firehawk® has been introduced in 67 countries and regions across Asia, Europe, the Americas, Africa, and Oceania, with plans for commercial expansion in North America following the positive TARGET-FIRST study results [4]

Firehawk╱火鹰支架是该集团自主研发的第三代冠脉药物洗脱支架系统，兼具了药物洗脱支架"低再狭 窄率"的特性和裸金属支架"极低晚期血栓率"的优势。该系统采用间断式单面凹槽载药与药聚合物控释 设计，严密包裹在槽内的药物╱涂层聚合物在抵达血管病变区后才释出，实现雷帕霉素"定向、定时、 定量"靶向释放。药物载荷仅为常规的三分之一，涂层面积也仅占金属总面积的5%左右，基本保持了裸 支架的结构形态，从而使Firehawk╱火鹰支架在保持其药物支架属性和基本功能的同时，实现与裸支架 相当的快速内皮化愈合效果。TARGET-FIRST研究进一步验证了在涂层面积和载药量方面尽可能迫近裸 支架这一集团独特设计理念的系统性临床获益。 《新英格兰医学杂志》以高影响因子、严格的同行评审和强大的全球学术影响力著称，位居世界医学四 大顶级期刊之首，其权威性被公认为评价科创和临床成果的最高标准。欧洲心脏病学年会亦是全球顶尖 的心血管学术盛会。这种通过"顶级期刊快速通道+顶级学术会议核心专场"同步亮相的情况极为罕见， 仅限于突破性强、能迅速改变全球临床实践和具有重大公共卫生意义的开创性研究成果;TARGET- FIRST研究获此殊荣和礼 ...